RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). Article

fiu authors

publication date

  • May 20, 2013

Digital Object Identifier (DOI)

volume

  • 31

issue

  • 15_suppl